Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.40 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | RORC | P51449 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3414469 | 0.98 | CHRM2 (0.39) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL2490415 | 0.88 | CHRM2 (0.40) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL126114 | 0.87 | CHRM2 (0.42) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL4183479 | 0.86 | SLC6A3 (0.34) | CHRM1TSHRNPSR1TP53 | |
| SCHEMBL5062392 | 0.83 | CHRM2 (0.40) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL21832231 | 0.82 | USP2 (0.33) | TSHRUSP2 | |
| SCHEMBL4239133 | 0.81 | KMT2A (0.43) | CHRM2CHRM1ALDH1A1KDM4EKMT2A | |
| SCHEMBL3911963 | 0.80 | CHRM2 (0.39) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL22345800 | 0.78 | CHRM2 (0.46) | CHRM2CHRM1ALDH1A1OPRD1KDM4E | |
| SCHEMBL1486106 | 0.78 | SLC6A3 (0.38) | MAPTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12582670-B2 | Lignin solvation using aqueous biologically compatible buffers | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-03-24 | — | — | US | claimed |
| US-20260047995-A1 | COSMETIC COMPOSITION OF STABILIZED RETINOID BY PH BUFFER | MARY KAY INC (US) | 2026-02-19 | — | — | US | claimed |
| US-20250312297-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-10-09 | — | — | US | claimed |
| US-20250302777-A1 | METHODS FOR TREATING GASTROPARESIS | EVOKE PHARMA, INC. | 2025-10-02 | — | — | US | claimed |
| EP-3880688-B1 | OLIGOSACCHARIDE PREPARATIONS AND COMPOSITIONS | DSM IP ASSETS BV (NL) | 2025-09-17 | — | — | EP | claimed |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | EVOKE PHARMA, INC. | 2025-07-17 | — | — | US | claimed |
| WO-2025064521-A1 | ULTRAFILTRATION / DIAFILTRATION PURIFICATION METHODS | PROFOUNDBIO US CO. (US) | 2025-03-27 | — | — | WO | claimed |
| US-12194009-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| US-12194008-B2 | Nasal formulations of metoclopramide | EVOKE PHARMA, INC. (US) | 2025-01-14 | — | — | US | claimed |
| WO-2024137814-A1 | REDUCTION OF HEALTHCARE RESOURCE UTILIZATION BY PATIENTS TREATED WITH INTRANASALLY-ADMINISTERED METOCLOPRAMIDE | EVOKE PHARMA, INC (US) | 2024-06-27 | — | — | WO | claimed |
| WO-2003042250-A1 | COMPOSITION AND METHOD TO HOMOGENEOUSLY MODIFY OR CROSS-LINK CHITOSAN UNDER NEUTRAL CONDITIONS | BIOSYNTECH CANADA INC. (CA) | 2003-05-22 | — | — | WO | claimed |
| WO-2002083079-A9 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY L P (US) | 2003-04-10 | — | — | WO | claimed |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | DEY L.P. | 2003-03-20 | — | — | US | claimed |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | MYLAN PHARMACEUTICALS, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2002083113-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL AND A STEROID SUCH AS E.G. BUDESONIDE OR FLUTICASONE FOR DELIVERY INTO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| WO-2002083079-A2 | AEROSOL COMPOSITIONS CONTAINING FORMOTEROL FOR DELIVERY TO THE LUNGS VIA NEBULIZATION | DEY, L.P. (US) | 2002-10-24 | — | — | WO | claimed |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | MYLAN TECHNOLOGIES, INC. | 2002-10-17 | — | — | US | claimed |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | DEY L.P. | 2002-10-17 | — | — | US | claimed |
| EP-1229940-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA INC. (CA) | 2002-08-14 | — | — | EP | claimed |
| WO-2001036000-A1 | TEMPERATURE-CONTROLLED AND PH-DEPENDANT SELF-GELLING BIOPOLYMERIC AQUEOUS SOLUTION | BIO SYNTECH CANADA, INC. (CA) | 2001-05-25 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260047995-A1 | COSMETIC COMPOSITION OF STABILIZED RETINOID BY PH BUFFER | RARB, RARA, RARG | CHRM2 2658/4885CHRM1 2458/4885ALDH1A1 304/4885 |
| US-20020151597-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | CHRM2 23/4885CHRM1 46/4885ALDH1A1 2567/4885 |
| US-12194008-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885ALDH1A1 2584/4885 |
| US-20250228803-A1 | NASAL FORMULATIONS OF METOCLOPRAMIDE | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885ALDH1A1 2584/4885 |
| US-20030055026-A1 | Intended for administration as a nebulized aerosol; for therapy and prophylaxis symptoms of bronchocon-strictive disorders | SERPINA6, CALU, TSLP | CHRM2 187/4885CHRM1 422/4885ALDH1A1 2861/4885 |
| US-12582670-B2 | Lignin solvation using aqueous biologically compatible buffers | HCLS1, ASNS, EPAS1 | CHRM2 3969/4885CHRM1 3650/4885ALDH1A1 2561/4885 |
| US-20020183293-A1 | Administering durg comprising formoterol, or a derivative thereof and asteroidal anti-inflammatory agent, or a derivative in a pharmacologically suitable fluid, wherein the drug formulation is stable during long term storage | AREG, IL5, IL17A | CHRM2 202/4885CHRM1 344/4885ALDH1A1 3372/4885 |
| US-20020151598-A1 | Formoterol, or a derivative; long term storage stability | ADRB2, ADRA2C, ADRA2A | CHRM2 23/4885CHRM1 46/4885ALDH1A1 2567/4885 |
| US-12194009-B2 | Nasal formulations of metoclopramide | MC2R, MTNR1B, MC4R | CHRM2 659/4885CHRM1 1282/4885ALDH1A1 2584/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.